Invivo Partners has announced its investment in Signadori Bio, a pioneering biotech company founded through a collaboration between Sofinnova Partners, Gustave Roussy, and scientific founders Dr. Jean-Luc Perfettini and Prof. Nathalie Chaput.
Signadori Bio is a preclinical-stage biopharmaceutical company developing an innovative cell therapy platform to transform cancer treatment. The company’s proprietary platform originates from Gustave Roussy, a globally renowned oncology center.
This initiative is supported by Sofinnova’s €165M biotech acceleration fund, Biovelocita II, which focuses on advancing breakthrough science in Europe. “Advancing cell therapies from discovery to patients requires deep expertise, strategic guidance, and the right ecosystem. Invivo Partners’s strong track record in cell therapy will be instrumental in accelerating the company’s growth and bringing innovative treatments to the clinic,” noted Matthieu Coutet, CEO of Signadori Bio, and Partner at Sofinnova Partners.
This strategic investment underscores Invivo’s commitment to advancing next-generation cell therapies in oncology and reinforces its role as a key investor in early-stage biotech innovation. Alongside Sofinnova Partners, a recognized leader in life sciences investment, Invivo is actively shaping the future of advanced therapies by supporting transformative science from inception to impact.
“I’m honored to join forces with Sofinnova Partners in this bold endeavour. The science emerging from Gustave Roussy exemplifies the kind of innovation Invivo Partners was created to champion—disruptive, data-driven, and deeply rooted in clinical need. We’re thrilled to support this next chapter of oncology innovation.” — Laura Rodríguez, Partner at Invivo Partners.
About Invivo Partners
Invivo Partners is a venture capital firm specializing in early-stage life sciences companies. It is managed by Luis Pareras, Albert Ferrer, and Laura Rodríguez, with investments in 16 companies and three funds under management. The firm recently announced its third fund, targeting €100 million for investments in early-stage life science companies at the intersection of advanced therapies, synthetic biology, and artificial intelligence. Invivo Ventures III has a majority of private investors with the support of a number of institutional investors such as the European Investment Fund (EIF), Fond-ICO Next Tech, the Catalan Finance Institute and the Barcelona City Council.
More information: invivo.partners
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners manages over €4 billion in assets. For more information, please visit: sofinnovapartners.com.
About Gustave Roussy
Ranked by Newsweek magazine as the leading European Cancer Centre and fourth in the world, Gustave Roussy is a centre with comprehensive expertise and is devoted entirely to patients suffering with cancer. The Institute is a founding member of the Paris-Saclay Cancer Cluster. It is a source of diagnostic and therapeutic advances. It caters for almost 50,000 patients per year, including 3,500 children and adolescents, and its approach is one that integrates research, patient care and teaching. It is specialized in the treatment of rare cancers and complex tumors and it treats all cancers in patients of any age. Its care is personalized and combines the most advanced medical methods with an appreciation of the patient’s human requirements. In addition to the quality of treatment offered, the physical, psychological and social aspects of the patient’s life are respected. 4,100 professionals work on its two campuses: Villejuif and Chevilly-Larue. Gustave Roussy brings together the skills that are essential for the highest quality research in oncology: 40% of patients treated are included in clinical studies. For further information: www.gustaveroussy.fr.
About Gustave Roussy Transfert
Created in 2000, Gustave Roussy Transfert is Gustave Roussy’s subsidiary dedicated to the development and transfer of technologies. Its missions are (1) to create and identify innovations from all the research teams based at Gustave Roussy, (2) to set up and monitor translational partnerships involving Gustave Roussy, and (3) to source, promote and support Gustave Roussy’s entrepreneurial projects.
cloud technology axon
With a target size of €250 million, the fund aims to complete betwee...
